Biota tanks as its flu drug comes up empty in Phase II

Damian Garde Biota Pharmaceuticals' slow trip downward continued Friday as the company disclosed that its its lead program, a flu treatment called laninamivir octanoate, failed ...

Sanofi and Regneron prep their cardio contender for FDA review after a Phase III sweep

Damian Garde Sanofi and Regeneron are heading to the FDA with a potential blockbuster cardiovascular treatment, touting positive results from a slew Phase III trials in which the drug ...

Quark’s RNAi treatment misses the mark in a Phase II kidney trial

Damian Garde Quark Pharmaceuticals' gene-silencing treatment for kidney transplant complications missed its primary endpoint in a Phase II trial, possibly jeopardizing a deal with ...

Amgen’s kidney dialysis drug clears its first Phase III hurdle

Damian Garde Amgen's in-development treatment for patients on kidney dialysis met its primary and secondary goals in a late-stage trial, step one in the drug's three-part Phase ...

GlaxoSmithKline and Theravance eye Phase III for another COPD contender

Damian Garde The blockbuster duo of GlaxoSmithKline and Theravance are pushing a new respiratory combo therapy into late-stage study, pooling the active ingredients from its last two ...

Fresh off Phase III success, Otonomy shoots for an $86M IPO

Damian Garde San Diego biotech Otonomy isn't biding its time, filing to go public in an $ 86.3 million IPO just three days after unveiling positive Phase III results for its lead ...

Sanofi’s $1.5B dengue vaccine shows Phase III promise, but questions linger

Damian Garde Capping a 20-year effort to develop the world's first dengue fever vaccine, Sanofi has come through with positive results from a sweeping Phase III trial, but its candidate ...

AstraZeneca trumpets diabetes duo’s victory in Phase III

Tracy Staton While its top executives were prepping for a hearing on Pfizer's megamerger offer, AstraZeneca rolled out new data from a diabetes trial. The verdict? A combination ...

CURx picks up a Gilead cystic fibrosis drug ready for Phase III

Damian Garde San Diego startup CURx has paid an undisclosed sum to license an antiobitic developed by Gilead, planning to launch a Phase III trial on the drug to treat lung infections ...

Aveo’s cancer drug circles the drain after a scuttled Phase II trial

Damian Garde Aveo Oncology and Astellas Pharma are shutting down a Phase II study of tivozanib in breast cancer after failing to enroll enough patients, the partners announced. FierceBiotech ...

Peregrine Pharmaceuticals Starts Phase III Lung Cancer Trial

barbara.lempert Peregrine Pharmaceuticals Initiates Sunrise Pivotal Phase III Clinical Trial of Bavituximab in Second-Line Non-Small Cell Lung Cancer Company Launches www.SunriseTrial.com ...

Karolinska’s Axelar comes up short in Phase II with lung cancer drug

Damian Garde Swedish biotech Axelar's lung cancer drug failed to beat out standard docetaxel in a mid-stage trial, but bankroller Karolinska Development isn't giving up, planning ...
Page 3 of 1112345...10...Last »
© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS